News

For the third day in a row, shares of CymaBay Therapeutics (NASDAQ: CBAY) enjoyed a very healthy gain in price. That came on the announcement of a capital-raising effort by the company. Ultimately

Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) is no stranger to legal issues. The company is still dealing with a barrage of lawsuits alleging that its talc-based products gave customers

We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there

Cathie Wood is known for her propensity to buy growth stocks that have the chance to disrupt their industries while also making early investors rich. And that means she's a big buyer of biotech

As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3

On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector's stocks are down by

Sometimes, the laws of physics seem to apply to the stock market. That's especially the case when it comes to momentum. When certain stocks get a head of steam going, it's hard to slow them down.

Certain stocks tend to perform better in a bull market, while others show their strengths in bear times. If you add both of these types of stocks to your portfolio, you're likely to benefit over the

Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday.

The continued momentum is a result of

If, like many other investors, you've written off big pharma stocks because of their reputation for being slow-growing giants, Vertex Pharmaceuticals (NASDAQ: VRTX) might be the breath of fresh air

September has historically been the worst month for the S&P 500, a phenomenon called the "September effect." The next few weeks may or may not live up (or down) to these low expectations, but

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is firing on all cylinders. The company has performed better than the broader market in the past year as its core cystic fibrosis (CF) franchise

Live by the index, die by the index -- being included in a well-known collection of stocks can really help a company's visibility and boost investor morale. The opposite effect can kick in if it

Most of the time, high-yielding stocks aren't coupled with high target prices from Wall Street. Instead, high yields usually convey market uncertainty, which is usually tied to a lower price target

Over the past year, rising interest rates made dividend stocks a lot less appealing than fixed-income investments like CDs and bonds. They also broadly drove investors from tech stocks toward more

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Climate change

For any investment, getting it to $1 million can be a lofty goal to set. It's by no means an easy task, and will require a sizable buy-in, lots of patience, and good returns along the way. Below

Inflation is making life harder for everyone, including retirees who need to stretch out their savings to help cover additional costs. One way to help offset rising inflation is to invest in

If you've been an AT&T (NYSE: T) shareholder for some years now, I'm sure I don't have to tell you how turbulent a ride it has been. The telecom giant is down by more than 34% in the past three